iBB-Institute for Bioengineering and Biosciences and i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
Department of Bioengineering, Instituto Superior Técnico, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
Mar Drugs. 2022 Dec 30;21(1):34. doi: 10.3390/md21010034.
Marine microbiomes are prolific sources of bioactive natural products of potential pharmaceutical value. This study inspected two culture collections comprising 919 host-associated marine bacteria belonging to 55 genera and several thus-far unclassified lineages to identify isolates with potentially rich secondary metabolism and antimicrobial activities. Seventy representative isolates had their genomes mined for secondary metabolite biosynthetic gene clusters (SM-BGCs) and were screened for antimicrobial activities against four pathogenic bacteria and five pathogenic strains. In total, 466 SM-BGCs were identified, with antimicrobial peptide- and polyketide synthase-related SM-BGCs being frequently detected. Only 38 SM-BGCs had similarities greater than 70% to SM-BGCs encoding known compounds, highlighting the potential biosynthetic novelty encoded by these genomes. Cross-streak assays showed that 33 of the 70 genome-sequenced isolates were active against at least one species, while 44 isolates showed activity against at least one bacterial pathogen. Taxon-specific differences in antimicrobial activity among isolates suggested distinct molecules involved in antagonism against bacterial versus pathogens. The here reported culture collections and genome-sequenced isolates constitute a valuable resource of understudied marine bacteria displaying antimicrobial activities and potential for the biosynthesis of novel secondary metabolites, holding promise for a future sustainable production of marine drug leads.
海洋微生物组是具有潜在药用价值的生物活性天然产物的丰富来源。本研究检查了两个培养物集,其中包含 55 个属的 919 种与宿主相关的海洋细菌和一些迄今尚未分类的谱系,以鉴定具有潜在丰富次生代谢和抗菌活性的分离株。对 70 个代表性分离株的基因组进行了次生代谢产物生物合成基因簇(SM-BGC)的挖掘,并对其针对四种致病菌和五种致病菌的抗菌活性进行了筛选。总共鉴定出 466 个 SM-BGC,经常检测到与抗菌肽和聚酮合酶相关的 SM-BGC。只有 38 个 SM-BGC 与编码已知化合物的 SM-BGC 的相似度大于 70%,这突出了这些基因组所编码的潜在生物合成新颖性。十字划线试验表明,在 70 个测序的基因组分离株中,有 33 个对至少一种 种具有活性,而 44 个分离株对至少一种细菌病原体具有活性。分离株中针对细菌与 病原体的抗菌活性的分类群特异性差异表明,针对细菌与 病原体的拮抗作用涉及不同的分子。这里报道的培养物集和测序的分离株构成了具有抗菌活性和潜在新型次生代谢物生物合成能力的未充分研究的海洋细菌的宝贵资源,为未来海洋药物先导物的可持续生产提供了希望。